Novartis (NVS) Tops Q1 EPS by 13c, raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Novartis (NVS) PT Raised to $108 at CFRA
April 23, 2024 1:11 PM EDTCFRA analyst Wan Nurhayati raised the price target on Novartis (NYSE: NVS) to $108.00 (from $105.00) while maintaining a Hold rating.
The analyst comments "We raise our target price by $3 to $108, implying a 2024 P/E of 15.4x, largely in line with the peer average. Novartis... More
